Emulation of the SUNLIGHT Trial Using Specialty Oncology Electronic Health Records Databases
Emulation of the SUNLIGHT (NCT04737187) Trial Using Specialty Oncology Electronic Health Records Databases
This observational study uses existing U.S. specialty oncology electronic health records to emulate the SUNLIGHT trial. It compares survival among adults with metastatic colorectal cancer who began trifluridine-tipiracil plus bevacizumab or trifluridine-tipiracil alone after prior systemic treatment. Treatment was chosen during routine care; the study did not assign treatment. The main outcome is time to death from any cause. Investigators will compare the real-world estimate with the published estimate from the randomized SUNLIGHT trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Randomized controlled trials (RCTs) are generally regarded as the gold-standard of evidence for establishing efficacy of medical products. However, real-world data (RWD) are increasingly used to complement evidence from RCTs. Yet, to have confidence in the accuracy of non-interventional studies of medical products and their outcomes in oncology, investigators need to know what questions can be validly answered, with which non-interventional study designs, and which analysis methods are appropriate, given the data that is available. Building on a process from the RCT DUPLICATE initiative, EmulatioN of Comparative Oncology trials with Real-world Evidence (ENCORE) is the trial emulation discussed in this protocol, which is part of the expansion project specific to oncology and aims to emulate 12 randomized oncology RCTs using multiple EHR data sources.
The purpose of this protocol is to describe the emulation of the SUNLIGHT trial.5 SUNLIGHT was a Phase III, open-label, randomised study assessing the efficacy and safety of trifluridine-tipiracil (FTD-TPI) (35 mg/m²/dose orally BID; Given 5 days on / 2 days off schedule, for 2 weeks, followed by 14-day rest) plus bevacizumab (5 mg/kg intravenously on Day 1 and Day 15, every 4-week cycle) versus FTD-TPI alone (35 mg/m²/dose orally BID; Given 5 days on / 2 days off schedule, for 2 weeks, followed by 14-day rest) in patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Somerville, Massachusetts, United States, 02145
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adults with metastatic colorectal cancer who initiated FTD-TPI plus bevacizumab or FTD-TPI alone after two prior systemic treatment regimens for metastatic disease.
Description
Inclusion Criteria:
- Age 18 years or older at study regimen initiation.
- Metastatic colorectal cancer documented in the oncology electronic health record.
- Initiation of trifluridine-tipiracil (FTD-TPI) plus bevacizumab or FTD-TPI alone after two prior systemic treatment regimens for metastatic disease (third-line setting).
- Known RAS mutation status at or before study regimen initiation.
- Prior treatments included a fluoropyrimidine, irinotecan, and oxaliplatin. Prior anti-VEGF therapy was required for RAS-mutant disease; prior anti-VEGF or anti-EGFR therapy was required for RAS wild-type disease.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 when ascertainable in the electronic health record.
Exclusion Criteria:
- Anticancer treatment in the four weeks before study regimen initiation.
- Another primary malignancy in the five years before or on study regimen initiation, except adequately treated cervical carcinoma in situ or basal cell skin cancer.
- Prior FTD-TPI use.
- Other anticancer treatment during the treatment assessment window.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Initiation of trifluridine-tipiracil plus bevacizumab
|
Initiation of trifluridine-tipiracil (FTD-TPI) plus bevacizumab recorded in electronic health records is the exposure of interest. Treatment was selected in routine care, not assigned by this study.
Other Names:
|
|
Initiation of trifluridine-tipiracil alone
|
Initiation of trifluridine-tipiracil (FTD-TPI) without bevacizumab recorded in electronic health records is the reference exposure. Treatment was selected in routine care, not assigned by this study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to all-cause mortality (overall survival)
Time Frame: From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)
|
Hazard ratio with 95% confidence interval |
From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Shirley V Wang, PhD, ScM, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Intestinal Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colonic Diseases
- Colorectal Neoplasms
- Amino Acids, Peptides, and Proteins
- Proteins
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Bevacizumab
Other Study ID Numbers
Other Study ID Numbers
- 2022P002556-ENC-SUNLIGHT
- 75F40122C00181 (Other Grant/Funding Number: Food and Drug Administration)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.